BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 10363026)

  • 1. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
    Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
    Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
    Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
    J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships for acridine-substituted analogues of the mixed topoisomerase I/II inhibitor N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
    Spicer JA; Gamage SA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
    J Med Chem; 1997 Jun; 40(12):1919-29. PubMed ID: 9191970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Bridewell DJ; Finlay GJ; Baguley BC
    Anticancer Drug Des; 2001 Dec; 16(6):317-24. PubMed ID: 12375884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular uptake of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).
    Haldane A; Finlay GJ; Hay MP; Denny WA; Baguley BC
    Anticancer Drug Des; 1999 Jun; 14(3):275-80. PubMed ID: 10500502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
    Deady LW; Kaye AJ; Finlay GJ; Baguley BC; Denny WA
    J Med Chem; 1997 Jun; 40(13):2040-6. PubMed ID: 9207945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues.
    Osman S; Rowlinson-Busza G; Luthra SK; Aboagye EO; Brown GD; Brady F; Myers R; Gamage SA; Denny WA; Baguley BC; Price PM
    Cancer Res; 2001 Apr; 61(7):2935-44. PubMed ID: 11306471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
    Hicks KO; Pruijn FB; Baguley BC; Wilson WR
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1088-98. PubMed ID: 11356933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of cytotoxicity of N-[2-(dimethylamino)ethyl] acridine-4-carboxamide and of its 7-chloro derivative: the roles of topoisomerases I and II.
    Bridewell DJ; Finlay GJ; Baguley BC
    Cancer Chemother Pharmacol; 1999; 43(4):302-8. PubMed ID: 10071981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major groove binding and 'DNA-induced' fit in the intercalation of a derivative of the mixed topoisomerase I/II poison N-(2-(dimethylamino)ethyl)acridine-4-carboxamide (DACA) into DNA: X-ray structure complexed to d(CG(5-BrU)ACG)2 at 1.3-A resolution.
    Todd AK; Adams A; Thorpe JH; Denny WA; Wakelin LP; Cardin CJ
    J Med Chem; 1999 Feb; 42(4):536-40. PubMed ID: 10052960
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
    Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
    Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
    Wolf SJ; Wakelin LP; He Z; Stewart BW; Catchpoole DR
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1059-69. PubMed ID: 19277661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
    Finlay GJ; Riou JF; Baguley BC
    Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs.
    Haldane A; Finlay GJ; Baguley BC
    Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structure of the topoisomerase II poison 9-amino-[N-(2-dimethylamino)ethyl]acridine-4-carboxamide bound to the DNA hexanucleotide d(CGTACG)2.
    Adams A; Guss JM; Collyer CA; Denny WA; Wakelin LP
    Biochemistry; 1999 Jul; 38(29):9221-33. PubMed ID: 10413496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.
    Padget K; Stewart A; Charlton P; Tilby MJ; Austin CA
    Biochem Pharmacol; 2000 Sep; 60(6):817-21. PubMed ID: 10930536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 4-Hydroxymethyl-3-aminoacridine derivatives as a new family of anticancer agents.
    Charmantray F; Demeunynck M; Carrez D; Croisy A; Lansiaux A; Bailly C; Colson P
    J Med Chem; 2003 Mar; 46(6):967-77. PubMed ID: 12620073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding, and topoisomerase I inhibition activities.
    Bailly C; Qu X; Chaires JB; Colson P; Houssier C; Ohkubo M; Nishimura S; Yoshinari T
    J Med Chem; 1999 Jul; 42(15):2927-35. PubMed ID: 10425102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.